Crossmark

FOXA1 and AR in invasive breast cancer: new findings on their co-expression and impact on prognosis in ER-positive patients

Crossref DOI link: https://doi.org/10.1186/s12885-018-4624-y

Published Online: 2018-07-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rangel, Nelson

Fortunati, Nicoletta

Osella-Abate, Simona

Annaratone, Laura

Isella, Claudio

Catalano, Maria Graziella

Rinella, Letizia

Metovic, Jasna

Boldorini, Renzo

Balmativola, Davide

Ferrando, Pietro

Marano, Francesca

Cassoni, Paola

Sapino, Anna

Castellano, Isabella http://orcid.org/0000-0002-9072-1615
License Information

Text and Data Mining valid from 2018-07-03
More Information

Article History

Received: 31 May 2017

Accepted: 21 June 2018

First Online: 3 July 2018

Ethics approval and consent to participate

: The project provided an informed consent, obtained from the patients at the time of surgery due to the retrospective approach of the study, which did not impact on their treatment. The procedure for collecting the consent was approved by the Committee for human Biospecimen Utilization (Department of Medical Sciences – ChBU). “All the cases were anonymously recorded, and data were accessed anonymously”. The study was conducted in compliance with the Helsinki Declaration.

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.